Treatment of bone disease with dihydrotachysterol in patients undergoing long-term hemodialysis.
Nine of 24 patients undergoing long-term hemodialysis were found to have evidence of moderate to severe bone disease. Two had bone pain and muscle weakness and two had pseudofractures. Eight of the nine were treated with dihydrotachysterol (DHT), 0.25 to 0.375 mg/d initially, but four required doses between 0.5 and 1.0 mg/d. Ther serum alkaline phosphatase value decreased in all patients and returned to normal in six. The bone pain and muscle weakness resolved and the pseudofractures healed. Bone biopsies in six patients before and after initiation of treatment with DHT showed that the osteoid area decreased significantly from 29.6 +/- 22.8% (mean +/- standard deviation) to 11.5 +/- 7.5% (P less than 0.025) and the resorptive surface decreased in all patients. DHT, in doses of up to 1.0 mg/d, is effective in treating both the osteitis fibrosa and the osteomalacic components of bone disease in patients undergoing hemodialysis.
D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000473:pathology; D002118:Calcium / Q000097:blood; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D004097:Dihydrotachysterol / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D010018:Osteomalacia / Q000188:drug therapy; D011859:Radiography; D006435:Renal Dialysis
D004097:Dihydrotachysterol; D002118:Calcium